Vitamin B12 and Homocysteine Workup in Athletes: Why the 200-400 pg/mL Gray Zone Under-Flags Subclinical Deficiency, the Methylmalonic Acid Follow-On, and the Vegan-and-Endurance-Athlete Differential

A 33-year-old female triathlete arrives at intake three weeks out from a half-Ironman. Her training volume has held at 12-14 hours per week for the past four months, her power on the bike is up 6% over a year, her running splits have been trending in the wrong direction for six weeks, and her subjective read is that "the legs feel heavy on the runs even when everything else is normal." She has been on a plant-forward diet — largely vegetarian, occasional fish, no red meat for eight years — with a fortified nutritional-yeast source she uses "most days." A recent physical returned a serum B12 of 245 pg/mL flagged as in-range on the standard reference, an iron panel with ferritin at 42 ng/mL and hemoglobin at 13.4 g/dL, a TSH of 1.6 mIU/L, and a cortisol AM of 12 ug/dL. She reports intermittent numbness in her toes on long runs, has noticed her word-finding is slower on high-mileage weeks, and her partner has commented that she seems less patient than she used to be. The workup was passed as unremarkable and the recommendation she left with was "eat more consistently."

The serum B12 of 245 pg/mL that the standard reference flagged as normal is the exact number that the workup should not have stopped at. B12 reference ranges on most commercial panels sit at roughly 200 to 900 pg/mL. The lower end of that range was set decades ago against a general-population distribution and has been criticized in the clinical literature for missing subclinical B12 deficiency in patients whose serum B12 sits at 200-400 pg/mL but whose functional B12 status — measured by methylmalonic acid and homocysteine — is deficient. The at-risk populations are exactly the ones a sports RD sees frequently: plant-forward athletes, endurance athletes running elevated one-carbon-cycle demand, patients on PPIs or metformin, and older masters athletes with age-related atrophic gastritis. Reading the serum B12 in isolation misses these cases.

The integrated B12 workup reads serum B12 against methylmalonic acid, homocysteine, folate, the dietary pattern, the medication overlay, and the symptom cluster. It catches the subclinical deficiency the standard panel under-flags. It distinguishes true B12 deficiency from folate-driven homocysteine elevation. It flags the neurologic-symptom case that warrants medical referral. And it produces a chart trail that documents the differential defensibly.

Why the standard B12 reference range under-flags subclinical deficiency

Three structural reasons.

The lower reference bound is population-derived, not functionally validated. The 200 pg/mL floor was calibrated to catch overt megaloblastic anemia and the classic neurologic B12 deficiency syndrome. It performs adequately for those. It performs poorly for the subclinical case where methylmalonic acid — the functional marker of tissue-level B12 adequacy — is already elevated at serum B12 values of 200-400 pg/mL. The clinical literature has repeatedly documented that patients in this "gray zone" have measurably elevated MMA and homocysteine and clinical symptoms that improve with B12 repletion. The standard panel does not surface these cases.

Serum B12 measures circulating B12, not the fraction bound to transcobalamin II — the biologically active form. Roughly 20-30% of serum B12 is bound to transcobalamin II (holotranscobalamin, or "active B12") and is the fraction delivered to tissues. The remainder is bound to haptocorrin and is not readily bioavailable. A patient with normal total B12 and low active B12 has a subclinical deficiency the standard panel does not detect. Where the assay is available, holotranscobalamin is a more sensitive early marker.

The athlete's one-carbon-cycle demand runs elevated relative to the sedentary reference population. High-volume aerobic training raises the flux through the methionine-homocysteine cycle, which depends on folate, B12, and B6. The athlete with a serum B12 of 245 pg/mL and a heavy training load may have a functional deficiency the same value would not produce in a sedentary matched control. The reference range was not built against the trained-athlete population.

The six-dimension B12 workup

Dimension 1: Serum B12 read against the "gray zone." Values above roughly 500 pg/mL are typically adequate absent malabsorption. Values under 200 pg/mL are diagnostic for deficiency and warrant immediate medical evaluation. Values between 200 and 400 pg/mL are the gray zone — the standard panel calls them normal; the functional markers frequently do not. The interpretive frame is that the gray zone is a trigger for the follow-on workup, not a stopping point.

Dimension 2: Methylmalonic acid — the functional B12 marker. MMA is elevated when tissue-level B12 is inadequate because methylmalonyl-CoA cannot be converted to succinyl-CoA. Reference ranges vary by lab but a serum MMA above roughly 0.4 umol/L (or a urine MMA above the lab's reference) in the setting of a gray-zone serum B12 is highly suggestive of functional deficiency. MMA is more specific than homocysteine for B12 status because it is not confounded by folate or B6 status. Order MMA on every gray-zone serum B12, on every plant-forward athlete regardless of serum B12, and on every case where the symptom cluster suggests B12 deficiency and the standard panel is uninformative.

Dimension 3: Homocysteine — the folate-B12 interaction marker. Homocysteine rises when either B12 or folate is inadequate because both are required cofactors for the methionine-synthase reaction that regenerates methionine from homocysteine. An elevated homocysteine (typically above 15 umol/L, tighter thresholds around 10-12 umol/L in some clinical frames) in the setting of a gray-zone B12 is consistent with functional B12 deficiency, folate deficiency, or both. Homocysteine plus MMA disambiguates: elevated MMA plus elevated homocysteine implicates B12; normal MMA plus elevated homocysteine implicates folate or B6.

Dimension 4: Folate status and the folate-B12 masking pattern. High folate intake (from fortified grains, leafy greens, and folate-containing supplements) can normalize the megaloblastic-anemia hematologic picture of B12 deficiency while the neurologic damage progresses. The plant-forward athlete on a high-folate diet is exactly the case where the CBC looks unremarkable, the serum B12 sits in the gray zone, and the neurologic symptom cluster is the first surface signal. Capture folate intake carefully; capture supplemental folate especially; capture the RBC folate value where available.

Dimension 5: Medication and GI-status overlay. Proton-pump inhibitors, H2 blockers, and metformin all reduce B12 absorption over time — PPIs through impaired acid-mediated release of B12 from dietary protein, metformin through a less-understood ileal mechanism. Chronic use over years produces gradually declining B12 status that the standard panel catches late. Bariatric-surgery history, celiac disease, Crohn's disease, and any history of pernicious anemia in first-degree relatives shift the pre-test probability of B12 deficiency substantially upward. Capture the medication list, the GI history, and the family history at every intake; re-verify at every recheck.

Dimension 6: Symptom-cluster capture. Peripheral paresthesias (numbness or tingling in feet or hands), gait unsteadiness, subjective cognitive slowing, mood changes, glossitis, and unexplained fatigue that does not respond to fueling adjustment are the clinical surface of B12 deficiency. The symptoms are non-specific in isolation but the cluster is informative and the neurologic signs specifically shift the workup toward the medical-referral threshold. Capture the symptom cluster explicitly at intake; document onset, progression, and any correlation with training load.

The four-quadrant clinical decision matrix

Quadrant 1: Serum B12 above 500 pg/mL, no gray-zone concern, no symptom cluster, no medication or dietary risk factor. B12 status is adequate. Document and monitor at annual cadence; no follow-on workup indicated.

Quadrant 2: Serum B12 in the 200-400 pg/mL gray zone, or plant-forward diet, or medication overlay, but no symptom cluster. Run MMA and homocysteine. Normal MMA and homocysteine confirm the gray-zone serum value as functionally adequate; elevated MMA is the trigger for the repletion protocol and the folate-and-B6 workup. Recheck in 12 weeks after intervention.

Quadrant 3: Serum B12 in the gray zone paired with symptom cluster (paresthesias, cognitive slowing, mood), or elevated MMA on the follow-on. Repletion protocol (typically 1000 mcg oral daily, or IM injection if malabsorption is suspected) and referral to the primary-care team for the neurologic workup. Follow-up at 6-8 weeks with repeat MMA and symptom assessment.

Quadrant 4: Serum B12 below 200 pg/mL, or neurologic signs on exam (loss of vibration sense, positive Romberg, gait ataxia), or macrocytic anemia on the CBC, or symptom cluster with any red-flag feature (rapid progression, bilateral weakness, cognitive changes affecting function). Medical referral is the primary action, not the dietetic intervention. The sports-RD role is co-management around the medical workup, not stand-alone management.

The vegan and endurance-athlete differential

Two populations warrant a lower threshold for the MMA follow-on regardless of the serum B12 value.

The plant-forward athlete. Vegans, most vegetarians, and any athlete whose animal-food intake has been below one serving per day for over a year sits at elevated risk. Fortified foods (nutritional yeast, plant milks, some cereals) supply variable and often inadequate amounts; supplementation with 250-1000 mcg per day of cyanocobalamin or methylcobalamin is the standard preventive recommendation. The RD who is not verifying B12 status with MMA in this population is under-workup by convention. The 245 pg/mL serum B12 in the intake case above is the exact number the workup should have expanded on.

The high-volume endurance athlete regardless of dietary pattern. The elevated one-carbon-cycle demand raises the odds that a low-normal serum B12 is functionally inadequate. Endurance athletes on omnivorous diets are not immune. Capture the serum B12 as part of the annual bloodwork; run the MMA when the value sits in the gray zone or when the symptom cluster warrants.

When to refer to medical

Five signals warrant medical referral beyond the dietetic workup.

Serum B12 below 200 pg/mL on a confirmed draw. Overt deficiency; medical workup for pernicious anemia, malabsorption, and neurologic status.

Elevated MMA persisting after 12 weeks of adequate repletion. Suggests malabsorption or inadequate oral dosing; IM cobalamin and gastroenterology or hematology workup.

Neurologic signs on exam or rapidly progressive neurologic symptoms. Sensory deficits, gait ataxia, cognitive changes affecting daily function are all urgent-referral triggers regardless of the lab pattern.

Macrocytic anemia on the CBC. MCV above roughly 100 fL with any B12 or folate abnormality warrants a coordinated hematology workup.

Family history of pernicious anemia, or personal history of gastric surgery, bariatric surgery, ileal resection, or autoimmune disease. Pre-test probability shifts substantially; the medical workup drives.

Common counseling mistakes

Reading serum B12 as a single-number screen and stopping at "normal." The gray zone is not normal for at-risk populations; MMA is the disambiguator.

Recommending high-dose oral supplementation without confirming absorption in the malabsorption case. Metformin, PPI, atrophic-gastritis, and post-bariatric athletes may require sublingual, intranasal, or intramuscular routes; oral 1000 mcg is not universally effective in this subset.

Missing the folate-driven homocysteine picture and reflexively adding B12. Elevated homocysteine with normal MMA points toward folate or B6, not B12; the intervention differs.

Failing to capture the symptom cluster explicitly. Peripheral neuropathy, subjective cognitive slowing, and mood changes are the most sensitive early clinical signals; passing "no symptoms" on the record because the athlete did not volunteer them is a documentation failure.

Delaying medical referral on the neurologic case. B12-deficiency neurologic damage can become permanent if repletion is delayed; the RD role in the neurologic-symptom presentation is early referral, not extended dietetic trial.

Treating the plant-forward athlete's B12 as an incidental finding rather than a standing workup axis. The B12 status of the vegan or long-term vegetarian athlete is a longitudinal marker to track annually with MMA, not a one-off during a fatigue workup.

Where this lands in the SOAP

Subjective section format:

```

B12 Status Workup (panel reviewed YYYY-MM-DD):

• Serum B12: [X pg/mL, gray-zone Y/N]
• Methylmalonic acid: [X umol/L, or NOT ORDERED]
• Homocysteine: [X umol/L, or NOT ORDERED]
• Serum folate: [X ng/mL] / RBC folate: [X, or NOT ORDERED]
• Holotranscobalamin (active B12): [X, or NOT AVAILABLE]
• CBC — MCV: [X fL], Hgb: [X g/dL]

Dietary and medication overlay:

• Dietary pattern: [vegan / vegetarian / pescatarian / omnivorous]
• Duration of current dietary pattern: [X years]
• Estimated animal-food servings per day: [X]
• B12-fortified sources: [nutritional yeast, plant milks, cereals — frequency]
• Current supplement: [B12 form, dose, frequency, adherence]
• Medications: [PPI, H2 blocker, metformin, other]
• GI history: [gastric surgery, celiac, Crohn's, atrophic gastritis, pernicious anemia in family]

Symptom cluster:

• Peripheral paresthesias: [none / intermittent / persistent, distribution]
• Gait steadiness: [normal / occasional / concerning]
• Cognitive symptoms: [none / word-finding / concentration / memory]
• Mood changes: [none / irritability / low mood]
• Glossitis: [none / present]
• Fatigue pattern: [training-load-linked vs training-independent]

Quadrant: [1-4 from clinical matrix]

Clinical impression: [statement integrating serum B12, MMA, homocysteine, folate, dietary and medication overlay, symptom cluster]

Action: [MMA/homocysteine order / repletion protocol / medical referral / observation]

Follow-up: [recheck date, plan, escalation triggers]

```

Assessment integrates the lab pattern with the dietary and medication overlay and the symptom cluster. Plan documents the differential, the repletion protocol where applicable, the medical-coordination communications, and the recheck cadence. See [SOAP notes for sports dietitians](/blog/soap-notes-for-sports-dietitians) for the broader documentation framework.

The homocysteine-and-cardiovascular thread

Homocysteine sits on the workup for its B12 and folate diagnostic value; it also carries a cardiovascular-risk signal independent of the vitamin workup. Elevated homocysteine is an independent cardiovascular risk marker in some frames, and the athlete with an unexplained homocysteine elevation warrants the paired [lipid workup](/blog/lipid-panel-interpretation-in-athletes) and cardiovascular-history capture. The clinical decisions differ — homocysteine-lowering B-vitamin trials have not consistently reduced cardiovascular events, so the intervention is not solely homocysteine-driven — but the integrated cardiometabolic read benefits from the added variable.

The masters-athlete and female-athlete threads

Masters athletes over 50 develop atrophic gastritis at rates that shift B12 pre-test probability upward independent of dietary pattern; run the MMA annually in this population regardless of the serum B12 value. Peri- and post-menopausal shifts do not directly change B12 physiology, but the co-occurring iron, thyroid, and vitamin D shifts in this population warrant an integrated read across the [iron-status workup](/blog/iron-status-workup-in-female-athletes), the [thyroid workup](/blog/thyroid-screening-sports-nutrition-intake-workup), and the [vitamin D workup](/blog/vitamin-d-status-workup-in-athletes).

Where platform tooling helps

The bottleneck in the B12 workup at scale is the multi-axis integration — the gray-zone serum B12 against the MMA and homocysteine follow-on, the folate confounder, the dietary and medication overlay, the symptom cluster, the recheck trajectory across years. Doing this by hand drops the integration on busy weeks; the plant-forward athlete's B12 gets passed as normal at 245 pg/mL and the workup surfaces months later with a neurologic symptom that could have been intercepted at intake.

The leverage is a B12-status workup module that ingests serum B12 with automatic gray-zone flagging, prompts for MMA and homocysteine on the gray-zone or at-risk case, captures dietary pattern and medication overlay, surfaces the symptom cluster prompts, tracks folate to catch the masking pattern, generates the four-quadrant decision matrix, pre-populates the SOAP documentation, and tracks the medical-coordination communications when referral is warranted. The RD's job is the clinical judgment and the conversation, not the spreadsheet.

The chart trail is defensible — every interpretation tied to the integration context that justified it, every referral documented with the lab pattern and symptom cluster that drove it, every repletion protocol paired with the recheck cadence that closes the loop.

The bottom line

B12 status in athletes is a multi-axis read, not a single-number screen. The 200-400 pg/mL gray zone is where the standard panel under-flags subclinical deficiency, and the exact populations the sports RD sees frequently — plant-forward athletes, high-volume endurance athletes, athletes on PPIs or metformin, masters athletes — are the populations where the gray zone is diagnostically informative.

The workup that catches the real cases reads serum B12 against MMA and homocysteine, captures folate to disambiguate the masking pattern, integrates the dietary and medication overlay, captures the symptom cluster explicitly, and refers to medical on the neurologic or overt-deficiency presentations.

The 33-year-old triathlete with the 245 pg/mL B12, the plant-forward diet, the intermittent toe paresthesias, and the cognitive slowing is a Quadrant 2 or Quadrant 3 case pending the MMA — not the "unremarkable workup" the standard panel produced. The intake that runs the structured workup catches the difference. The intake that reads the serum B12 in isolation does not.

[Calsanova's Dietitian plan](/signup?role=dietitian) ships a B12-status workup module with serum-B12 gray-zone flagging, MMA and homocysteine follow-on prompts, folate integration, dietary-and-medication overlay capture, symptom-cluster prompts, four-quadrant decision-matrix surfacing, and pre-populated SOAP documentation with medical-coordination communications. Start your 30-day free trial and turn the B12 line on the standard panel from a single-number pass-fail into the clinical instrument that catches the subclinical cases the reference range collapses.